Amgen (AMGN) to Release Quarterly Earnings on Tuesday

Amgen (NASDAQ:AMGN) is projected to release its Q4 2025 results after the market closes on Tuesday, February 3rd. Analysts expect Amgen to post earnings of $4.74 per share and revenue of $9.4558 billion for the quarter. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 3, 2026 at 4:30 PM ET.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. Amgen’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period last year, the company posted $5.58 EPS. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Stock Performance

NASDAQ AMGN opened at $349.69 on Tuesday. Amgen has a 1-year low of $261.43 and a 1-year high of $350.43. The company has a market cap of $188.30 billion, a PE ratio of 27.02, a price-to-earnings-growth ratio of 3.06 and a beta of 0.45. The stock’s 50 day simple moving average is $332.23 and its 200-day simple moving average is $308.04. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 73.57%.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. HSBC reiterated a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research report on Tuesday, November 11th. BMO Capital Markets boosted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. The Goldman Sachs Group increased their price target on shares of Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, Piper Sandler lifted their price target on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and a consensus price target of $339.71.

Insider Activity at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. Insiders own 0.69% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Ameriprise Financial Inc. grew its stake in shares of Amgen by 16.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,467,959 shares of the medical research company’s stock valued at $688,649,000 after buying an additional 345,242 shares during the period. AQR Capital Management LLC increased its stake in Amgen by 194.3% during the second quarter. AQR Capital Management LLC now owns 269,260 shares of the medical research company’s stock valued at $74,981,000 after purchasing an additional 177,767 shares during the last quarter. Worldquant Millennium Advisors LLC boosted its stake in Amgen by 497.7% in the second quarter. Worldquant Millennium Advisors LLC now owns 203,205 shares of the medical research company’s stock valued at $56,737,000 after acquiring an additional 169,209 shares during the period. Amundi lifted its stake in Amgen by 4.6% in the third quarter. Amundi now owns 2,408,089 shares of the medical research company’s stock valued at $708,267,000 after buying an additional 104,920 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI grew its position in Amgen by 557.4% in the 3rd quarter. Zurich Insurance Group Ltd FI now owns 119,651 shares of the medical research company’s stock worth $33,766,000 after purchasing an additional 101,451 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.